New radioactive drug targets Hard-to-Treat prostate cancer
NCT ID NCT07363486
First seen Jan 24, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This early-stage trial tests a new drug called 225Ac-LNC1011 in 9 men with a type of advanced prostate cancer that no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells using a targeting molecule (PSMA). The main goals are to find the safest and most effective dose and to see if it can shrink tumors or lower PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.